VIVK News this morning!!

[RAZOR11]

I just got alerted on VIVK. VIVK is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. Comapny came with news this morning and looks like its setting itself up for a strong run next week. Awesome time to take a position in this one. Here is the latest news

Vivakor Announces Substantial Reduction of Company's Long Term Debt Position and Finalizes Health America Inc. Acquisition

CORALVILLE, Iowa, Jun 4, 2010 (GlobeNewswire via COMTEX) -- Vivakor, Inc. (OTCBB:VIVK) today announced the Company has reduced its long and short term debt by an additional $510,000 by converting those debts to shares of common stock. This substantial debt reduction through conversion to stock finalizes the acquisition payments for Health America Inc. and the VIVASLICES MRI software technology, which the company purchased in August of 2008. VIVASLICES is a software technology which increases image resolution of previous generations of MRI units, thereby saving hospitals and clinics with older equipment millions of dollars in costs related to purchasing new MRI units with enhanced image resolution capacity.

Vivakor Executive Chairman Matt Nicosia added this statement to the news: "This reduction of the Company's debt represents both the positive outlook by management and its creditors as we make progress on both the commercialization of VIVASLICES and other Vivakor technologies. Additionally the Company has now eliminated all of its long term debt, which increases shareholder equity and improves the balance sheet. This elimination of long term debt allows the Company to devote its resources to technology commercialization and development. We look forward to completing the Company's financing needs which will add to the Company's sustainability and improve the outlook for Vivakor."

[Chuck.W]

Vivakor Announces Receipt of LOI for $600k Investment

.Companies:Vivakor, Inc..Press Release Source: Vivakor, Inc. On Friday June 4, 2010, 4:30 pm EDT

CORALVILLE, Iowa, June 4, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK - News) today announced that the Company has received a letter of intent for an investment up to $600,000 from Excelsior Management. The terms of the transaction are for an investment in restricted common stock at $0.08 per share or shares registered in the current S-1 at the S-1 price of $0.23 per share.



Vivakor Chairman Matt Nicosia added this statement to the news: "This investment interest in Vivakor coincides with management's belief that the Company is currently undervalued and validates management's efforts to create value by reducing debt and increasing the viability of its technologies. We look forward to increasing the Company's value through pushing forward commercialization efforts for both VIVASLICES and VIVASIGHT."



About Vivakor, Inc.



Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at .

[stocksalot]

Press Release Source: Vivakor, Inc. On Friday June 4, 2010, 4:30 pm EDT

CORALVILLE, Iowa, June 4, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK - News) today announced that the Company has received a letter of intent for an investment up to $600,000 from Excelsior Management. The terms of the transaction are for an investment in restricted common stock at $0.08 per share or shares registered in the current S-1 at the S-1 price of $0.23 per share.



Vivakor Chairman Matt Nicosia added this statement to the news: "This investment interest in Vivakor coincides with management's belief that the Company is currently undervalued and validates management's efforts to create value by reducing debt and increasing the viability of its technologies. We look forward to increasing the Company's value through pushing forward commercialization efforts for both VIVASLICES and VIVASIGHT."



About Vivakor, Inc.



Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at .



FORWARD-LOOKING STATEMENTS



This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

[gucci88]

Vivakor, Inc. recently announced that its management increased the revenue outlook for its VivaThermic division. Increased global demand for disposable products used to support the stem cell research and therapy markets is following aggressive private and public funding of these markets. Vivakor's VivaThermic vials improve cryopreservation of sensitive cell types such as human stem cells. The potential market size for their VivaThermic vials has increased and could potentially be in excess of $20 million annually.


looking for a reversal play monday. positive buying volume will definitely show this. reversal at .046 last trade at .0369.
found a video chart on VIVK with stockhideout's own TI reviewing chart.. TechSmith | Screencast.com, online video sharing, VIVK for June 7th 2010

[stocksamongus]

Great support here @ .037. Look for positive movement this week with Friday's press release. All that's important is said in the video chart posted above. There is a trend here indicating we will see VIVK move quickly in the upward direction traders; be alert!

[mickymoose99]

VIVK_K
+5.69% With A Days Range of 0.0369 X .05
The MA20 @ 0.047 / MA50 @ 0.072
IMO cuold see VIVK_K test or possible push thru
Resistance @ .05 This Week
Record breaking volume 18 X The Daily Avg
RSI @ 41.90
MAC D pulled away from the signal
Hister Gram showing Positive Diversion
ULT In The Buyers Range @ 45.47
News After the Close Friday
Vivakor Announces Receipt of LOI for $600k Investment

Vivakor, Inc. (OTC:VIVK) New "Featured Report"

Click here to Watch a Video Chart of VIVK(+8.4%)

For more information Visit their Web Site

Keep your in Portfolio

[mickymoose99]

.Vivakor Extends Its Business Development Agreement With Baker Consulting

Buzz up! 0 Print..Companies:Vivakor, Inc..Related Quotes
Symbol Price Change
VIVK.OB 0.03 -0.01


{"s" : "vivk.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: Vivakor, Inc. On Monday June 7, 2010, 6:14 pm EDT

CORALVILLE, Iowa, June 7, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK - News) has extended its Business Development agreement with Baker Consulting out of Walnut Creek, California and its affiliate group, Kyouko Group, Inc. out of South Florida for an additional six months. Baker Consulting has made great strides in assisting the company with distribution agreements and research collaboration. Vivakor's Chairman Matt Nicosia stated recently, "Baker Consulting, with its vast experience in medical device commercialization and corporate finance, has been very instrumental in our Company's commercialization efforts and we are very pleased in the progress that has been made thus far and we look forward to creating great value for Vivakor shareholders through this relationship."



About Vivakor, Inc.



Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handing and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at .

[stocksamongus]

Vivakor Expands Market for VivaSight Technologies to Adult Vision Care and Further Increases Revenue Outlook

.Companies:Vivakor, Inc..Press Release Source: Vivakor, Inc. On Tuesday June 8, 2010, 7:46 pm EDT

CORALVILLE, Iowa, June 8, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK - News) announced new markets for its VivaSight technologies and further increased revenue projections for its VivaSight division. The new market mainly includes adult vision care to be used by Ophthalmologists and Optometrists. Speaking about this new development, Matt Nicosia, Vivakor's Chairman, said, "Adult vision care is a growing market with an aging population. Existing vision screening devices do not properly detect adult issues and our technology has the capability of addressing this need. VivaSight technology is useful mainly for children's screening but has the potential to be a very valuable asset in adult vision care. Our devices use cutting edge technology developed by our multidisciplinary research model to save time and money while enhancing exactness in all our detection efforts."



Additionally, VivaSight technologies will be marketed as the best and most versatile vision screening devices on the market. Mr. Matt Nicosia stated, "The market for vision screening is not just limited to United States vision care. We have received significant attention through our commercialization partners for international use of the VivaSight technology for both private practice and government mandated vision care." This announcement will expand upon Vivakor's recently released revenue projections for its VivaSight division and increase the estimated market to $50 million annually.



About Vivakor, Inc.



Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at .

[stocksalot]

Vivakor Expands Market for VivaSight Technologies to Adult Vision Care and Further Increases Revenue Outlook.Baker Consulting has made great strides in assisting the company with distribution agreements and research collaboration.Has been issuing major headlines about their developments in the biomedical technology sector.Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine aimed to help with MRI techology.Check out their web-site: .........
VIVK chart!------IMO Should start to see an uptrend towards the MA20 @ .04 for 50 X 100 % Gain